Literature DB >> 19683272

Longer wait times increase overall mortality in patients with bladder cancer.

Girish S Kulkarni1, David R Urbach, Peter C Austin, Neil E Fleshner, Andreas Laupacis.   

Abstract

PURPOSE: We used population level data to determine the impact of extended wait times on the survival of patients who underwent radical cystectomy for bladder cancer.
MATERIALS AND METHODS: We identified 2,535 patients who underwent cystectomy for bladder cancer in Ontario, Canada between 1992 and 2004 using administrative databases. A Cox proportional hazards model accounting for patient, pathological and health services variables that could affect wait times was created to assess the impact of wait time on survival. The tumor stage specific impact of waiting for cystectomy was also assessed. Cox regression analysis that modeled wait time using cubic splines was used to determine a maximum wait time within which optimal care can be provided.
RESULTS: Median wait time from transurethral bladder resection to cystectomy was 50 days. Unadjusted and adjusted analyses demonstrated that prolonged wait times were significantly associated with a lower overall survival rate. The relative hazard of death with increasing wait times appeared greater for low stage vs high stage cancers. The cubic splines regression analysis revealed that the risk of death began to increase after 40 days.
CONCLUSIONS: Treatment delay between transurethral bladder tumor resection and radical cystectomy resulted in worse overall survival. The effect of wait time was greatest in lower stage lesions. The suggested maximum wait time from transurethral bladder tumor resection to cystectomy was 40 days. Further studies assessing disease-free survival are required to corroborate these findings.

Entities:  

Mesh:

Year:  2009        PMID: 19683272     DOI: 10.1016/j.juro.2009.06.041

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  37 in total

1.  Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Authors:  Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2019-01-31       Impact factor: 1.862

2.  An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer.

Authors:  Valeria Panebianco; Ettore De Berardinis; Giovanni Barchetti; Giuseppe Simone; Constantino Leonardo; Marcello Domenico Grompone; Maurizio Del Monte; Davide Carano; Michele Gallucci; James Catto; Carlo Catalano
Journal:  Eur Radiol       Date:  2017-02-08       Impact factor: 5.315

3.  Referral processes and wait times in primary care.

Authors:  Ieva Neimanis; Kathryn Gaebel; Robert Dickson; Richard Levy; Cindy Goebel; Angelo Zizzo; Anne Woods; John Corsini
Journal:  Can Fam Physician       Date:  2017-08       Impact factor: 3.275

Review 4.  [Transurethral en bloc resection of non-muscle invasive bladder cancer. What is the state of the art?].

Authors:  M W Kramer; M Wolters; I F Abdelkawi; A S Merseburger; U Nagele; A Gross; T Bach; M A Kuczyk; T R W Herrmann
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

5.  Waiting for a specialist consultation for a new condition in Ontario: impacts on patients' lives.

Authors:  Daniel W Harrington; Kathi Wilson; Mark W Rosenberg
Journal:  Healthc Policy       Date:  2014-05

Review 6.  Implementing risk-aligned bladder cancer surveillance care.

Authors:  Florian R Schroeck; Nicholas Smith; Jeremy B Shelton
Journal:  Urol Oncol       Date:  2018-02-13       Impact factor: 3.498

Review 7.  Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival.

Authors:  Vincent Bourgade; Sarah J Drouin; David R Yates; Jerôme Parra; Marc-Olivier Bitker; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-03-02       Impact factor: 4.226

Review 8.  Timing of curative treatment for prostate cancer: a systematic review.

Authors:  Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel
Journal:  Eur Urol       Date:  2013-02-22       Impact factor: 20.096

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada.

Authors:  Michael Metcalfe; Wassim Kassouf; Ricardo Rendon; David Bell; Jonathan Izawa; Joseph Chin; Anil Kapoor; Edward Matsumoto; Jean-Baptiste Lattouf; Fred Saad; Louis Lacombe; Yves Fradet; Adrian Fairey; Niels-Eric Jacobson; Darryl Drachenberg; Ilias Cagiannos; Alan So; Peter Black
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.